Evidence map›Paper›PMID 40796804›Full record

ArticleNature communications2025

Epigenetic control of topoisomerase 1 activity presents a cancer vulnerability.

Tae-Hee Lee, Colina X Qiao, Vladislav Kuzin, Yuepeng Shi, Marina Farkas, Zhiyan Zhao, Vijayalalitha Ramanarayanan, Tongyu Wu, Tianyi Guan, Xianzhen Zhou and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. The Red AlgaCurrent issues in molecular biology · 2026
    Article
  2. Article
  3. Article
  4. Visualizing DNA repair factor recruitment at sites of transcription in single cells.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2026
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Tae-Hee LeeDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-6263-6499
Colina X QiaoDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Vladislav Kuzin *Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Yuepeng Shi *Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Marina FarkasProgram of Myeloid Neoplasms, Program of Applied Epigenetics, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Zhiyan ZhaoDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Vijayalalitha RamanarayananDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tongyu WuDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tianyi GuanDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xianzhen ZhouDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0009-0005-9862-6347
David CorujoProgram of Myeloid Neoplasms, Program of Applied Epigenetics, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-7930-0935
Marcus BuschbeckProgram of Myeloid Neoplasms, Program of Applied Epigenetics, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-3218-4567
Laura BaranelloDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-6039-1849
Philipp OberdoerfferDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. PO@jhmi.edu.ORCID http://orcid.org/0000-0002-2484-1440

Funding

SPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Amanda Nickles Fader · 2018 to 2026
$20.5M
Epigenetic mechanisms controlling single-stranded DNA lesion sensitivity and mutagenesisR01CA285725 · NCI · JOHNS HOPKINS UNIVERSITY · PI Philipp Oberdoerffer · 2024 to 2026
$2.6M
Probing the mechanisms that control DNA repair pathway choice.R35GM153484 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Philipp Oberdoerffer · 2024 to 2026
$1.5M
Cancerfonden (Swedish Cancer Society) 21 1771 Pj01 HKarolinska Institutet (Karolinska Institute) 2-190/2022Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation) KAW 2016.0161Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation) KAW 2022.0189Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation) KAW 2022.0380Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PID2021-126907NB-I00NCI NIH HHS P50 CA228991NCI NIH HHS R01 CA285725NIGMS NIH HHS R35 GM153484U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01CA285725U.S. Department of Health & Human Services | National Institutes of Health (NIH) R35GM153484Vetenskapsrådet (Swedish Research Council) 2021-02630 VR
6 · The paper itself

Abstract

DNA transactions introduce torsional constraints that pose an inherent risk to genome integrity. While topoisomerase 1 (TOP1) activity is essential for DNA supercoil removal, the aberrant stabilization of TOP1:DNA cleavage complexes (TOP1ccs) can result in cytotoxic DNA lesions. What protects genomic hot spots of topological stress from excessive TOP1cc accumulation remains unknown. Here, we identify chromatin context as an essential means to coordinate TOP1cc resolution. Through its ability to bind poly(ADP-ribose) (PAR), the histone variant macroH2A1.1 facilitates TOP1cc repair factor recruitment and lesion turnover, thereby preventing DNA damage in response to transcription-associated topological stress. The alternatively spliced macroH2A1.2 isoform is unable to bind PAR or protect from TOP1ccs. Impaired macroH2A1.1 splicing, a frequent cancer feature, was predictive of increased sensitivity to TOP1 poisons in a pharmaco-genomic screen in breast cancer cells, and macroH2A1.1 inactivation mirrored this effect. We propose macroH2A1 alternative splicing as an epigenetic modulator of TOP1-associated genome maintenance and a potential cancer vulnerability.

Indexed as

Breast NeoplasmsDNA Topoisomerases, Type IEpigenesis, GeneticNeoplasmsAlternative SplicingCell Line, TumorChromatinDNA DamageFemaleHistonesHumansChromatinDNA Topoisomerases, Type IHistonesmacroH2A histoneTOP1 protein, human

Identifiers

PMID40796804
PMCPMC12343833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.